Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Genscript Biotech Corporation (G51.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
2.2000-0.0390 (-1.74%)
At close: 08:16AM CET
Advertisement
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.
Currency in EUR

Valuation Measures4

Yahoo Finance Plus required to access annual data
Annual
Quarterly
Yahoo Finance Plus required to access monthly data
Monthly
Subscribe to Yahoo Finance Plus Essential to download historical data
 
As of Date: 3/11/2023
Current
Market Cap (intraday)
5.04B
Enterprise Value
4.06B
Trailing P/E
N/A
Forward P/E
N/A
PEG Ratio (5 yr expected)
N/A
Price/Sales (ttm)
8.87
Price/Book (mrq)
6.95
Enterprise Value/Revenue
6.93
Enterprise Value/EBITDA
-7.98

Trading Information

Stock Price History

Beta (5Y Monthly) 1.34
52-Week Change 3-21.16%
S&P500 52-Week Change 3-12.21%
52 Week High 33.9880
52 Week Low 31.8690
50-Day Moving Average 32.8385
200-Day Moving Average 32.8861

Share Statistics

Avg Vol (3 month) 368
Avg Vol (10 day) 3N/A
Shares Outstanding 52.12B
Implied Shares Outstanding 6N/A
Float 81.14B
% Held by Insiders 138.31%
% Held by Institutions 124.71%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4Jun 06, 2017
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in USD.

Fiscal Year

Fiscal Year Ends Dec 31, 2021
Most Recent Quarter (mrq)Jun 30, 2022

Profitability

Profit Margin -66.18%
Operating Margin (ttm)-64.13%

Management Effectiveness

Return on Assets (ttm)-11.65%
Return on Equity (ttm)-55.74%

Income Statement

Revenue (ttm)586.17M
Revenue Per Share (ttm)0.28
Quarterly Revenue Growth (yoy)32.70%
Gross Profit (ttm)303.48M
EBITDA -329.46M
Net Income Avi to Common (ttm)-387.94M
Diluted EPS (ttm)-0.1700
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)1.26B
Total Cash Per Share (mrq)0.6
Total Debt (mrq)501.15M
Total Debt/Equity (mrq)56.41
Current Ratio (mrq)2.92
Book Value Per Share (mrq)0.36

Cash Flow Statement

Operating Cash Flow (ttm)-162.93M
Levered Free Cash Flow (ttm)-240.53M
Advertisement
Advertisement